Drugs & Targets MD Anderson, C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy February 16, 2024Vol.50 No.07
Drugs & Targets BioNTech, Autolus form CAR T-cell therapy collaboration to advance pipeline and expand late-stage programs February 16, 2024Vol.50 No.07
NCI Kimryn Rathmell: Flat funding in FY24 would mean more cuts to NCI programsNew NCI director to continue the National Cancer Plan set in motion by predecessor Monica Bertagnolli February 09, 2024Vol.50 No.06By Alexandria Carolan
Capitol Hill House committee issues subpoena for NIH’s Monica Bertagnolli to address NIH sexual misconduct policies February 09, 2024Vol.50 No.06By Matthew Bin Han Ong
Conversation with The Cancer Letter Shikha Jain, Shea Holman: It’s time for NIH to be transparent about how misconduct cases are handled February 09, 2024Vol.50 No.06By Matthew Bin Han Ong
Conversation with The Cancer Letter Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024 February 09, 2024Vol.50 No.06By Paul Goldberg and Matthew Bin Han Ong
Trials & Tribulations Florez Laboratory at Dana-Farber launches International Pregnancy and Lung Cancer Registry February 09, 2024Vol.50 No.06By Narjust Florez, Lauren Keil, Rebekah Kaufman and Oyepeju Abioye-Akintola
In Brief Karen Lu named executive vice president, physician-in-chief at Moffitt February 09, 2024Vol.50 No.06
In Brief William Nelson named chair of the SU2C scientific advisory committee February 09, 2024Vol.50 No.06
In Brief Andrew Evens, Linda Tanzer named to expanded deputy director positions at Rutgers February 09, 2024Vol.50 No.06
